Skip to main content

Prevalence of Pathogenic Variants and Variants of Uncertain Significance in Patients With Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis

In brief

Adding more repair genes triples uncertain findings in ovarian cancer testing

Across 19 studies of 3,323 patients, 24% had at least one pathogenic variant and 11% had a variant of uncertain significance. Expanding testing to additional homologous recombination repair genes raised uncertain findings from 5% to 14%, suggesting broader panels bring more ambiguity; which genes merit routine testing remains unsettled.

Journal
Human mutation (Q1)
Published
16 November 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
Wenhao Zhang, Daijuan Chen, Jing Zeng, Rutie Yin, Xiang-Yu Meng, Qingli Li
PMID
43042162
DOI
10.1155/humu/3005037

Why clinicians should know about it

  • Picked for Genetics (clinical) (top studies of the week, 22 November 2026): Meta-analysis informs ovarian cancer variant interpretation and panel testing

Abstract

Variants of uncertain significance (VUS) are increasingly identified when using multigene panel next-generation sequencing (NGS) for epithelial ovarian cancer (EOC) patients. This meta-analysis is aimed at estimating the prevalence of pathogenic variants (PV) and VUS in EOC patients receiving multigene panel testing. We retrieved pertinent literature from PubMed, EMBASE, and the Cochrane Library, following the PRISMA 2020. Our analysis included 19 studies involving 3323 patients. Meta-analysis of proportions via logit transformation was performed. At the gene level, the pooled proportion of tested genes in which at least one PV was detected was 82%, and the corresponding proportion for VUS was 87%. At the patient level, 24% of patients carried at least one PV, and 11% carried at least one VUS. BRCA1/2 mutations accounted for the majority (22%) of PV within the homologous recombination repair (HRR) pathway, whereas expanding testing to additional HRR panels tripled the VUS rate (from 5% to 14%). The difference between PV prevalence and VUS prevalence was significantly greater for classic DNA damage repair (DDR) genes than for other panel genes. BRCA1, BRCA2, RAD51D, and RAD51C exhibited the greatest disparities in the proportions of PV and VUS, indicating a positive risk-benefit balance regarding clinical decision-making. Our findings suggest that the probability of detecting a VUS in other panel genes is significantly higher than in classic DDR genes, highlighting the underreporting of VUS in clinical studies. Routine clinical reporting may prioritize well-established EOC-risk genes, with multigene panel testing reserved for selected subgroups. Improving the reporting and classification of VUS is essential, and future studies should prioritize gene-specific VUS evaluation.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.